"We are pleased to have the opportunity to present our hGH-CTP program to the leading growth hormone academic and industry researchers from around the globe who will be participating in this important meeting," noted Dr. Abraham Havron, CEO of PROLOR. "We are especially honored to be one of only three companies selected to participate in the scientific program. This Congress provides us a valuable forum for raising awareness of our longer-acting growth hormone product, which has the potential to provide important benefits to the many patients requiring growth hormone therapy."
PROLOR's hGH-CTP presentation is scheduled for 10:45 am ET on October 4, 2010. The 5th International Congress will be held at the Sheraton New York Hotel in New York City from October 3-6, 2010.
For more information about the conference, visit http://www.5grs-igf.org.About The Growth Hormone Research Society The Growth Hormone Research Society (GRS) was founded in 1992 to provide a forum for the study and exchange of ideas on all aspects of growth hormone physiology, and diseases involving abnormalities of the GH axis. With over 400 members from more than 30 countries, the society represents a unique international body composed of clinicians, scientists, educators, and students. These individuals are committed to the advancement and dissemination of research and education on a milieu of medical and biological topics related to GH. The GRS holds biannual meetings in conjunction with its sister society, the IGF Society.
ABOUT PROLOR BIOTECHPROLOR Biotech, Inc. is a biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting, biobetter, proprietary versions of already-approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technolog
|SOURCE PROLOR Biotech, Inc.|
Copyright©2010 PR Newswire.
All rights reserved